JP Morgan Chase
CYTK icon

JP Morgan Chase’s Cytokinetics CYTK Stock Holding History

JP Morgan Chase’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,200
Closed -$292K – 7379
2024
Q4 		$292K Sell
6,200
-36,200
-85% -$1.88M ﹤0.01% 5310
2024
Q3 		$2.24M Buy
42,400
+36,200
+584% +$2.02M ﹤0.01% 3913
2024
Q2 		$336K Sell
6,200
-146,200
-96% -$8.82M ﹤0.01% 4892
2024
Q1 		$10.7M Sell
152,400
-361,500
-70% -$28M ﹤0.01% 2419
2023
Q4 		$42.9M Buy
+513,900
New +$18.6M ﹤0.01% 1303

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's CYTK Position: Q1 2026 in Review

JP Morgan Chase reduced its Cytokinetics (CYTK) stake by 36% in Q1 2026, selling an estimated $32.3M and leaving 903,805 shares worth $56.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

JP Morgan Chase first reported a position in CYTK in Q3 2013 and has held it in 38 quarters since. The position peaked at $89.8M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • JP Morgan Chase held 903,805 shares of Cytokinetics worth $56.9M as of Q1 2026.
  • JP Morgan Chase sold 508,992 Cytokinetics shares in Q1 2026, an estimated $32.3M.
  • Cytokinetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1309 holding.
  • JP Morgan Chase first reported a position in Cytokinetics in Q3 2013 and has held it in 38 quarters since.
  • JP Morgan Chase's Cytokinetics position peaked at $89.8M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.